

PRESS RELEASE
March 5, 2007



MPM Capital BioVentures IV Holds Final Close on \$550 Million

GREENWICH, CONN. — Atlantic-Pacific Capital, Inc., the largest independent global placement agent for alternative investment funds and direct private placements, is pleased to announce the final close of MPM Capital's fourth healthcare venture fund, MPM BioVentures IV. Returning limited partners — including GE Healthcare Financial Services, Itochu, the Kauffman Foundation, and Scottish Widows Investment Partnership — comprise over half of the \$550 million in committed capital. New investors include AlpInvest, Dow Employees' Pension Plan, Skandia, and Union Carbide Employees' Pension Plan.

MPM BioVentures IV made its first investment in the second quarter of 2006, and since then its team has actively been building the portfolio that now consists of seven companies. The fund intends to spread its investments among biotechnology and medical technology products, across the life-cycle of entrepreneurial companies, with 85% focused on biotech and specialty pharmaceuticals and 15% on medtech, tools, and diagnostics. The fund's preferred investment size is \$20 million to \$50 million per company.

"Our LPs reacted particularly positively to our proven ability to invest across the full spectrum of company stages and our reinforced capabilities and commitment to support our companies — not only in discovery, but also in clinical development and commercialization. With this fund, we will continue to take a leadership role in financing the most promising healthcare companies in the U.S. and abroad," said Luke Evnin, Founding General Partner. "We are very pleased with the support from, and enthusiasm shown by, the LP community for this fund."

"Institutional investors recognized MPM's unparalleled domain expertise in life sciences, which will continue to result in early recognition of trends and investment opportunities. The deep and varied experience of the expansive MPM team has been critical in assessing and developing complex assets and supporting companies," stated Ed Chestnut, Partner at Atlantic-Pacific Capital. "It was a pleasure to work with a firm of partners that truly believe in each other and their ability to deliver superior results for their portfolio companies and limited partners. Atlantic-Pacific congratulates the entire MPM Capital team on closing their fourth fund, and we wish them and their investors continued success."

About MPM Capital

MPM Capital L.P. is a global investment management firm focused solely on life sciences investing. One of the largest investment management firms dedicated to the life sciences sector, MPM Capital has offices in Boston, San Francisco and New York City. MPM's portfolio ranges from start-ups to large capitalization public

companies, with a primary focus on biopharmaceutical and medical device companies nearing commercialization of products or those companies that already offer product-driven opportunities. The firm manages over \$2.5 billion in assets through the MPM BioVentures Family of venture capital funds and the MPM BioEquities public market fund. More information on MPM can be found at www.mpmcapital.com.

Atlantic-Pacific Capital, Inc., Member FINRA and SIPC

For more information: Alex Leykikh: E: aleykikh@apcap.com Ph: 203-862-9182